Streetbeat News

ALLR

Allarity Therapeutics, Inc.

https://www.allarity.com

Industry

Biotechnology

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

Open

1.40

Mkt cap

1.9M

Volume

365K

High

1.40

P/E Ratio

-0.13

52-wk high

666.00

Low

1.27

Div yield

N/A

52-wk low

1.26

Exicure, Inc. (NASDAQ:XCUR) shares surged 179.9% in pre-market trading after receiving a Nasdaq listing extension. Other notable pre-market movers include Zeo Energy Corp. (NASDAQ:ZEO) up 288.9%, Telesis Bio, Inc. (NASDAQ:TBIO) up 138.4%, and Venus Concept Inc. (NASDAQ:VERO) up 82.8%.

Portfolio Pulse from Avi Kapoor

September 19, 2024 | 9:26 am

Intel shares rose 6.9% in pre-market trading due to a strategic collaboration with AWS to advance US-based chip manufacturing. Several other stocks, including Galmed Pharmaceuticals and Smith Micro Software, also saw significant pre-market movements.

Portfolio Pulse from Avi Kapoor

September 17, 2024 | 9:48 am

Allarity Therapeutics (NYSE:ALLR) has seen a significant increase in short interest, with 40.86% of its float sold short, a 5654.93% rise since the last report. This high short interest compared to its peers could indicate bearish sentiment, but it may also present a bullish opportunity if the stock price rises.

Portfolio Pulse from Benzinga Insights

September 16, 2024 | 7:00 pm

Allarity Therapeutics announced that two patients in their Phase 2 trial for stenoparib in advanced ovarian cancer have exceeded one year of treatment, showing durable clinical benefits. This highlights the potential of stenoparib, a dual PARP/Tankyrase inhibitor, in heavily pre-treated patients.